Skip to main content
FRMSL logo

FRMSL — Investor Relations & Filings

Ticker · 4746 ISIN · TW0004746003 TW Manufacturing
Open in API
Filings indexed 1,872 across all filing types
Latest filing 2022-08-11 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 4746

About FRMSL

www.formosalab.com

Formosa Laboratories, Inc. is a Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company provides integrated services ranging from process development and custom synthesis to large-scale commercial manufacturing. Its core product portfolio includes UV-filters, Vitamin D derivatives, and polymers such as cholesterol and phosphate binders. Formosa Laboratories offers specialized expertise in Antibody-Drug Conjugates (ADCs) and injectable manufacturing, including cytotoxic and freeze-dried products. Maintaining high quality standards, its facilities are cGMP-compliant and have been successfully inspected by the US FDA, TFDA, EDQM, and PMDA. The company serves a global clientele, providing one-stop solutions for complex chemical synthesis, fermentation, and peptide production.

Recent filings

Filing Released Lang Actions
111年第2季資產負債表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated balance sheet with detailed financial data for multiple periods, including specific dates such as June 30, 2022 (111年06月30日) and December 31, 2021 (110年12月31日). The presence of comprehensive financial statements with asset, liability, and equity breakdowns indicates this is a financial report rather than a brief announcement or certification. The length of the document (5102 characters) and the detailed financial data suggest it is an Interim / Quarterly Report rather than a full Annual Report (10-K) or an Earnings Release (which typically contains summarized highlights). The document is not a regulatory filing or announcement but contains substantive financial data for a period shorter than a full fiscal year (quarterly data). Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-08-11 Chinese
111年第2季權益變動表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial tables showing changes in equity for the first half of the year 2022 (民國111年上半年度) and the same period in the previous year. The data includes components such as common stock, capital surplus, legal surplus reserve, undistributed earnings, and other equity items. This type of detailed financial data with period-specific figures and comparative analysis is characteristic of an Interim / Quarterly Report (IR). The document length is 4113 characters, which is sufficient to contain substantive financial data rather than just an announcement or certification. There is no indication that this is a full annual report or an earnings release summary. Therefore, the classification is Interim / Quarterly Report (IR).
2022-08-11 Chinese
本公司今日與重要子公司台新藥股份有限公司共同召開重大 訊息說明記者會之新聞稿內容
Regulatory Filings Classification · 95% confidence The document is a press release or announcement regarding a significant information disclosure event by the company (台耀化學股份有限公司) and its important subsidiary about clinical trial results of a drug (APP13007). It details the clinical trial data and outcomes but does not contain comprehensive financial statements or detailed financial performance data. The document length is 2239 characters, which is relatively short and reads like a news release or announcement rather than a full report. There is no indication that this is an annual report, interim report, earnings release, or any other formal financial filing. It is also not a regulatory certification or officer attestation. The content is primarily about clinical trial results and a news conference, which fits best under a general regulatory announcement or miscellaneous filing category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-08-09 Chinese
本公司重要子公司台新藥股份有限公司APP13007第三期臨床 試驗CPN-302取得顯著有效的主要療效數據
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a listed company (台耀) about the significant clinical trial results of its important subsidiary's drug APP13007. It includes specific clinical trial data, dates, and future plans related to the drug development. The document is 3627 characters long, which is relatively short and does not contain comprehensive financial statements or detailed financial analysis. It is primarily a regulatory announcement about a clinical trial result, not a financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is a regulatory announcement about a material event related to the company’s operations and research progress. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-08-09 Chinese
本公司經證交所同意自111年8月10日起恢復交易
Regulatory Filings Classification · 95% confidence The document is a short announcement from a listed company (ticker 4746 台耀) stating that the stock trading suspension has been lifted and trading will resume from a specific date (111/08/10). It mentions the suspension due to pending material information and the approval by the stock exchange to resume trading. The document is brief (541 characters) and does not contain any financial data, detailed reports, or management commentary. It is an official regulatory announcement about trading status rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-09 Chinese
111年07月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by company insiders, including directors, supervisors, and senior management. It lists current holdings, pledged shares, and related party holdings. The content focuses on insider share transactions and holdings rather than financial results, governance policies, or meeting materials. There is no indication of a report publication, earnings release, or regulatory certification. The document is not a general regulatory announcement but specifically reports insider shareholdings and pledges. Therefore, it fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 4170 characters, which is consistent with a detailed insider shareholding report rather than a brief announcement or a full financial report.
2022-08-09 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.